Summary

Medical monotherapy by functional class (NYHA) (currently available in Switzerland)
Recommendation, evidence	Class II	Class III	Class IV
I, A	Ambrisentan Bosentan Sildenafil	Ambrisentan Bosentan Sildenafil IV Epoprostenol	IV Epoprostenol
I, B	Macitentan Tadalafil Riociguat Selexipag	SC Treprostinit Macitentan Tadalafil Riociguat Inhaled Iloprost Treprostinil Selexipag
Ila, C		IV Iloprost IV Treprostinil
Ilb, C			Ambrisentan Bosentan Macitentan Sildenafil Tadalafil Riociguat Inhaled Iloprost IV Iloprost SC Treprostinil IV Treprostinil

Initial drug combination therapy by functional class (NYHA) (currently available in Switzerland)
Recommendation, evidence	Class II	Class III	Class IV
I, A
I, B	Ambrisentan + tadalafild	Ambrisentan + tadalafild
Ila, C	Other ERA + PDE-5i	Other ERA PDE-5i Bosentan + sildenafil + i.v. epoprostenol Bosentan + i.v. epoprostenol	Bosentan + sildenafil + i.v. epoprostenol Bosentan + i.v. epoprostenol
Ilb, C		Other ERA or PDE-5i + s.c. treprostinil Other ERA or PDE-5i + other i.v. prostacyclin analogues	Ambrisentan + tadalafild Other ERA+ PDE-5i Other ERA or PDE-5i + s.c. treprostinil Other ERA or PDE-5i + other i.v. prostacyclin analogues